Skip to main content
Top
Published in: Current Heart Failure Reports 6/2016

01-12-2016 | Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas

Authors: Mahmoud Traina, Sheba Meymandi, Jason S. Bradfield

Published in: Current Heart Failure Reports | Issue 6/2016

Login to get access

Abstract

Chagas disease affects millions of people worldwide. Though the majority of infected individuals remain asymptomatic, approximately 30 % of patients progress to develop cardiac manifestations and eventual heart failure. While vectorial transmission occurs predominantly in South America, Central America, and Mexico, millions of people originally from these endemic regions immigrate to non-endemic countries in North America, Europe, and Asia. Outside of rare specialized centers, health-care providers lack experience diagnosing and treating this disease. This lack of experience likely leads to far fewer Chagas disease patients being diagnosed than what actually exist in non-endemic countries, with subsequent adverse effect on patient outcomes and health-care expenses. Underdiagnosis increases the risk of developing cardiomyopathy, associated heart failure, and life-threatening ventricular arrhythmias as the disease progresses.
Literature
1.
2.
go back to reference Sarkar S, Strutz SE, Frank DM, Rivaldi CL, Sissel B, Sanchez-Cordero V. Chagas disease risk in Texas. PLoS Negl Trop Dis. 2010;4. Sarkar S, Strutz SE, Frank DM, Rivaldi CL, Sissel B, Sanchez-Cordero V. Chagas disease risk in Texas. PLoS Negl Trop Dis. 2010;4.
3.
go back to reference Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52:1922–30.CrossRefPubMed Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52:1922–30.CrossRefPubMed
4.
go back to reference Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, et al. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more? Matern Child Health J. 2008;12:283–6.CrossRefPubMed Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, et al. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more? Matern Child Health J. 2008;12:283–6.CrossRefPubMed
5.
go back to reference • Requena-Mendez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540. This systemic review and meta-analysis is an essential study that helps better quantify the prevalence of CD in Latin American immigrants living in Europe. • Requena-Mendez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540. This systemic review and meta-analysis is an essential study that helps better quantify the prevalence of CD in Latin American immigrants living in Europe.
6.
go back to reference Leiby DA, Herron Jr RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–55.CrossRefPubMed Leiby DA, Herron Jr RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–55.CrossRefPubMed
7.
go back to reference Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015;13:540–50.PubMedPubMedCentral Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015;13:540–50.PubMedPubMedCentral
8.
go back to reference Kirchhoff LV, Gam AA, Gilliam FC. American trypanosomiasis (Chagas’ disease) in Central American immigrants. Am J Med. 1987;82:915–20.CrossRefPubMed Kirchhoff LV, Gam AA, Gilliam FC. American trypanosomiasis (Chagas’ disease) in Central American immigrants. Am J Med. 1987;82:915–20.CrossRefPubMed
10.
go back to reference Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, et al. Autochthonous transmission of Trypanosoma cruzi. Louisiana Emerg Infect Dis. 2007;13:605–7.CrossRefPubMed Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, et al. Autochthonous transmission of Trypanosoma cruzi. Louisiana Emerg Infect Dis. 2007;13:605–7.CrossRefPubMed
11.
go back to reference Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4.CrossRefPubMed Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4.CrossRefPubMed
12.
go back to reference Traina MIKL, Khamag H, Padilla Garcia E, Meymandi S. Community-based study of prevalence of Chagas disease in Los Angeles County. 2010. Traina MIKL, Khamag H, Padilla Garcia E, Meymandi S. Community-based study of prevalence of Chagas disease in Los Angeles County. 2010.
13.
go back to reference Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymo RM, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion. 2008;48:1862–8.CrossRefPubMed Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymo RM, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion. 2008;48:1862–8.CrossRefPubMed
14.
go back to reference Avila Arzanegui O, Liendo Arenaza P, Martinez Indart L, Martinez Astorkiza T, Pocheville Guruceta MI, Egurbide Arberas MV. Prevalence of Trypanosoma cruzi infection and vertical transmission in Latin-American pregnant women in a health area of Biscay. Enferm Infecc Microbiol Clin. 2013;31:210–6.CrossRefPubMed Avila Arzanegui O, Liendo Arenaza P, Martinez Indart L, Martinez Astorkiza T, Pocheville Guruceta MI, Egurbide Arberas MV. Prevalence of Trypanosoma cruzi infection and vertical transmission in Latin-American pregnant women in a health area of Biscay. Enferm Infecc Microbiol Clin. 2013;31:210–6.CrossRefPubMed
15.
go back to reference Barona-Vilar C, Gimenez-Marti MJ, Fraile T, Gonzalez-Steinbauer C, Parada C, Gil-Brusola A, et al. Prevalence of Trypanosoma cruzi infection in pregnant Latin American women and congenital transmission rate in a non-endemic area: the experience of the Valencian Health Programme (Spain). Epidemiol Infect. 2012;140:1896–903.CrossRefPubMed Barona-Vilar C, Gimenez-Marti MJ, Fraile T, Gonzalez-Steinbauer C, Parada C, Gil-Brusola A, et al. Prevalence of Trypanosoma cruzi infection in pregnant Latin American women and congenital transmission rate in a non-endemic area: the experience of the Valencian Health Programme (Spain). Epidemiol Infect. 2012;140:1896–903.CrossRefPubMed
16.
go back to reference Munoz J, Coll O, Juncosa T, Verges M, del Pino M, Fumado V, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona. Spain Clin Infect Dis. 2009;48:1736–40.CrossRefPubMed Munoz J, Coll O, Juncosa T, Verges M, del Pino M, Fumado V, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona. Spain Clin Infect Dis. 2009;48:1736–40.CrossRefPubMed
17.
18.
go back to reference Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102 Suppl 1:75–85.CrossRefPubMed Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102 Suppl 1:75–85.CrossRefPubMed
19.
go back to reference Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD. The sero-prevalence of antibodies to trypanosoma cruzi in Latin American refugees and immigrants to Canada. J Immigr Minor Health. 2007;9:43–7.CrossRefPubMed Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD. The sero-prevalence of antibodies to trypanosoma cruzi in Latin American refugees and immigrants to Canada. J Immigr Minor Health. 2007;9:43–7.CrossRefPubMed
20.
go back to reference Jackson Y, Myers C, Diana A, Marti HP, Wolff H, Chappuis F, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis. 2009;15:601–3.CrossRefPubMedPubMedCentral Jackson Y, Myers C, Diana A, Marti HP, Wolff H, Chappuis F, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis. 2009;15:601–3.CrossRefPubMedPubMedCentral
21.
go back to reference Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol. 2014;103:1–10.CrossRefPubMed Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol. 2014;103:1–10.CrossRefPubMed
22.
go back to reference Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115:22–7.CrossRefPubMed Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115:22–7.CrossRefPubMed
23.
go back to reference Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, Seixas J, Van Gool T, Canavate C, Flores-Chavez M, Jackson Y, Chiodini PL, Albajar-Vinas P and Working Group on Chagas D. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16. Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, Seixas J, Van Gool T, Canavate C, Flores-Chavez M, Jackson Y, Chiodini PL, Albajar-Vinas P and Working Group on Chagas D. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16.
24.
go back to reference Munoz J, Gomez i Prat J, Gallego M, Gimeno F, Trevino B, Lopez-Chejade P, et al. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009;111:51–5.CrossRefPubMed Munoz J, Gomez i Prat J, Gallego M, Gimeno F, Trevino B, Lopez-Chejade P, et al. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009;111:51–5.CrossRefPubMed
25.
go back to reference Requena-Mendez A, Moore DA, Subira C, Munoz J. Addressing the neglect: Chagas disease in London. UK Lancet Glob Health. 2016;4:e231–3.CrossRefPubMed Requena-Mendez A, Moore DA, Subira C, Munoz J. Addressing the neglect: Chagas disease in London. UK Lancet Glob Health. 2016;4:e231–3.CrossRefPubMed
26.
go back to reference Pinto A, Pett S, Jackson Y. Identifying Chagas disease in Australia: an emerging challenge for general practitioners. Aust Fam Physician. 2014;43:440–2.PubMed Pinto A, Pett S, Jackson Y. Identifying Chagas disease in Australia: an emerging challenge for general practitioners. Aust Fam Physician. 2014;43:440–2.PubMed
27.
go back to reference Jackson Y, Pinto A, Pett S. Chagas disease in Australia and New Zealand: risks and needs for public health interventions. Trop Med Int Health. 2014;19:212–8.CrossRefPubMed Jackson Y, Pinto A, Pett S. Chagas disease in Australia and New Zealand: risks and needs for public health interventions. Trop Med Int Health. 2014;19:212–8.CrossRefPubMed
28.
go back to reference Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, et al. Chronic Chagas disease with advanced cardiac complications in Japan: case report and literature review. Parasitol Int. 2015;64:240–2.CrossRefPubMed Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, et al. Chronic Chagas disease with advanced cardiac complications in Japan: case report and literature review. Parasitol Int. 2015;64:240–2.CrossRefPubMed
29.
go back to reference Kapelusznik L, Varela D, Montgomery SP, Shah AN, Steurer FJ, Rubinstein D, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis. 2013;57:e7.CrossRefPubMed Kapelusznik L, Varela D, Montgomery SP, Shah AN, Steurer FJ, Rubinstein D, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis. 2013;57:e7.CrossRefPubMed
30.
go back to reference • Traina MI, Sanchez DR, Hernandez S, Bradfield JS, Labedi MR, Ngab TA, et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles. California Circ Heart Fail. 2015;8:938–43. This study demonstrates both the high prevalence of CD in Latin American immigrants living in Los Angeles with cardiomyopathy, but also the increased adverse event rate in the CD patients compared to patients with other etiologies for their non-ischemic cardiomyopathy. • Traina MI, Sanchez DR, Hernandez S, Bradfield JS, Labedi MR, Ngab TA, et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles. California Circ Heart Fail. 2015;8:938–43. This study demonstrates both the high prevalence of CD in Latin American immigrants living in Los Angeles with cardiomyopathy, but also the increased adverse event rate in the CD patients compared to patients with other etiologies for their non-ischemic cardiomyopathy.
31.
go back to reference Sanchez-Montalva A, Salvador F, Rodriguez-Palomares J, Sulleiro E, Sao-Aviles A, Roure S, et al. Chagas cardiomyopathy: usefulness of EKG and echocardiogram in a non-endemic country. PLoS One. 2016;11:e0157597.CrossRefPubMedPubMedCentral Sanchez-Montalva A, Salvador F, Rodriguez-Palomares J, Sulleiro E, Sao-Aviles A, Roure S, et al. Chagas cardiomyopathy: usefulness of EKG and echocardiogram in a non-endemic country. PLoS One. 2016;11:e0157597.CrossRefPubMedPubMedCentral
32.
go back to reference Stimpert KK, Montgomery SP. Physician awareness of Chagas disease. USA Emerg Infect Dis. 2010;16:871–2.CrossRefPubMed Stimpert KK, Montgomery SP. Physician awareness of Chagas disease. USA Emerg Infect Dis. 2010;16:871–2.CrossRefPubMed
33.
go back to reference El Ghouzzi MH, Boiret E, Wind F, Brochard C, Fittere S, Paris L, et al. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion. 2010;50:575–83.CrossRefPubMed El Ghouzzi MH, Boiret E, Wind F, Brochard C, Fittere S, Paris L, et al. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion. 2010;50:575–83.CrossRefPubMed
34.
go back to reference Atsma F, de Vegt F. The healthy donor effect: a matter of selection bias and confounding. Transfusion. 2011;51:1883–5.CrossRefPubMed Atsma F, de Vegt F. The healthy donor effect: a matter of selection bias and confounding. Transfusion. 2011;51:1883–5.CrossRefPubMed
35.
go back to reference Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico MC, Dramaix M, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg. 2004;70:201–9.PubMed Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico MC, Dramaix M, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg. 2004;70:201–9.PubMed
36.
go back to reference Buekens P, Cafferata ML, Alger J, Althabe F, Belizan JM, Carlier Y, et al. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: study protocol. Reprod Health. 2013;10:55.CrossRefPubMedPubMedCentral Buekens P, Cafferata ML, Alger J, Althabe F, Belizan JM, Carlier Y, et al. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: study protocol. Reprod Health. 2013;10:55.CrossRefPubMedPubMedCentral
37.
go back to reference Centers for Disease C and Prevention. Congenital transmission of Chagas disease—Virginia, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:477–9. Centers for Disease C and Prevention. Congenital transmission of Chagas disease—Virginia, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:477–9.
38.
go back to reference Leiby DA, Read EJ, Lenes BA, Yund AJ, Stumpf RJ, Kirchhoff LV, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas’ disease, in US blood donors. J Infect Dis. 1997;176:1047–52.CrossRefPubMed Leiby DA, Read EJ, Lenes BA, Yund AJ, Stumpf RJ, Kirchhoff LV, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas’ disease, in US blood donors. J Infect Dis. 1997;176:1047–52.CrossRefPubMed
39.
go back to reference Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion. 1999;39:310–5.CrossRefPubMed Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion. 1999;39:310–5.CrossRefPubMed
40.
go back to reference Sanchez DR, Traina MI, Hernandez S, Smer AM, Khamag H, Meymandi SK. Chagas disease awareness among Latin American immigrants living in Los Angeles. California Am J Trop Med Hyg. 2014;91:915–9.CrossRefPubMed Sanchez DR, Traina MI, Hernandez S, Smer AM, Khamag H, Meymandi SK. Chagas disease awareness among Latin American immigrants living in Los Angeles. California Am J Trop Med Hyg. 2014;91:915–9.CrossRefPubMed
41.
go back to reference Blasco-Hernandez T, Miguel LG, Navaza B, Navarro M, Benito A. Knowledge and experiences of Chagas disease in Bolivian women living in Spain: a qualitative study. Glob Health Action. 2016;9:30201.PubMed Blasco-Hernandez T, Miguel LG, Navaza B, Navarro M, Benito A. Knowledge and experiences of Chagas disease in Bolivian women living in Spain: a qualitative study. Glob Health Action. 2016;9:30201.PubMed
42.
go back to reference Minneman RM, Hennink MM, Nicholls A, Salek SS, Palomeque FS, Khawja A, et al. Barriers to testing and treatment for Chagas disease among Latino immigrants in Georgia. J Parasitol Res. 2012;2012:295034.CrossRefPubMedPubMedCentral Minneman RM, Hennink MM, Nicholls A, Salek SS, Palomeque FS, Khawja A, et al. Barriers to testing and treatment for Chagas disease among Latino immigrants in Georgia. J Parasitol Res. 2012;2012:295034.CrossRefPubMedPubMedCentral
43.
go back to reference Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3:e488.CrossRefPubMedPubMedCentral Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3:e488.CrossRefPubMedPubMedCentral
44.
go back to reference Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–34.CrossRefPubMed Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–34.CrossRefPubMed
45.
go back to reference Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370:1899–908.CrossRefPubMed Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370:1899–908.CrossRefPubMed
46.
go back to reference • Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373:1295–306. This prospective mulit-center trial (BENEFIT) compared benznidazole to placebo for the treatment of CD in patient with documented cardiomyopathy. • Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373:1295–306. This prospective mulit-center trial (BENEFIT) compared benznidazole to placebo for the treatment of CD in patient with documented cardiomyopathy.
47.
go back to reference Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51:e69–75.CrossRefPubMed Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51:e69–75.CrossRefPubMed
48.
go back to reference Miller DA, Hernandez S, De Armas Rodriguez L, Eells SJ, Traina MM, Miller LG, et al. Tolerance of benznidazole in a United States Chagas disease clinic. Clin Infect Dis. 2015;60:1237–40.CrossRefPubMed Miller DA, Hernandez S, De Armas Rodriguez L, Eells SJ, Traina MM, Miller LG, et al. Tolerance of benznidazole in a United States Chagas disease clinic. Clin Infect Dis. 2015;60:1237–40.CrossRefPubMed
49.
go back to reference Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13:342–8.CrossRefPubMedPubMedCentral Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13:342–8.CrossRefPubMedPubMedCentral
50.
go back to reference Rassi Jr A, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol. 2001;76:75–96.CrossRefPubMed Rassi Jr A, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol. 2001;76:75–96.CrossRefPubMed
51.
go back to reference Lee-Felker SA, Thomas M, Felker ER, Traina M, Salih M, Hernandez S, et al. Value of cardiac MRI for evaluation of chronic Chagas disease cardiomyopathy. Clin Radiol. 2016;71:618 e1–7.CrossRef Lee-Felker SA, Thomas M, Felker ER, Traina M, Salih M, Hernandez S, et al. Value of cardiac MRI for evaluation of chronic Chagas disease cardiomyopathy. Clin Radiol. 2016;71:618 e1–7.CrossRef
52.
go back to reference Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro AL. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. Europace. 2013;15:957–62.CrossRefPubMed Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro AL. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. Europace. 2013;15:957–62.CrossRefPubMed
53.
go back to reference Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes 3rd NA, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2012;126:1784–800.CrossRefPubMed Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes 3rd NA, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2012;126:1784–800.CrossRefPubMed
54.
go back to reference Sosa E, Scanavacca M, d’Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol. 1996;7:531–6.CrossRefPubMed Sosa E, Scanavacca M, d’Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol. 1996;7:531–6.CrossRefPubMed
55.
go back to reference Sosa E, Scanavacca M, D’Avila A, Bellotti G, Pilleggi F. Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease. Pacing Clin Electrophysiol. 1999;22:128–30.CrossRefPubMed Sosa E, Scanavacca M, D’Avila A, Bellotti G, Pilleggi F. Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease. Pacing Clin Electrophysiol. 1999;22:128–30.CrossRefPubMed
56.
go back to reference Saenz LC, Corrales FM, Bautista W, Traina M, Meymandi S, Rodriguez DA, Tellez LJ, Vaseghi M, Garcia F, Shivkumar K, Bradfield JS. Cardiac sympathetic denervation for intractable ventricular arrhythmias in Chagas disease. Heart Rhythm. 2016. Saenz LC, Corrales FM, Bautista W, Traina M, Meymandi S, Rodriguez DA, Tellez LJ, Vaseghi M, Garcia F, Shivkumar K, Bradfield JS. Cardiac sympathetic denervation for intractable ventricular arrhythmias in Chagas disease. Heart Rhythm. 2016.
57.
go back to reference Armaganijan LV, Staico R, Moreira DA, Lopes RD, Medeiros PT, Habib R, et al. 6-month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc Interv. 2015;8:984–90.CrossRefPubMed Armaganijan LV, Staico R, Moreira DA, Lopes RD, Medeiros PT, Habib R, et al. 6-month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc Interv. 2015;8:984–90.CrossRefPubMed
58.
go back to reference Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71:1833–8.CrossRefPubMed Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71:1833–8.CrossRefPubMed
59.
go back to reference Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13:3262–8.CrossRefPubMed Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13:3262–8.CrossRefPubMed
60.
go back to reference Requena-Mendez A, Albajar-Vinas P, Angheben A, Chiodini P, Gascon J, Munoz J, et al. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014;8:e3245.CrossRefPubMedPubMedCentral Requena-Mendez A, Albajar-Vinas P, Angheben A, Chiodini P, Gascon J, Munoz J, et al. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014;8:e3245.CrossRefPubMedPubMedCentral
Metadata
Title
Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas
Authors
Mahmoud Traina
Sheba Meymandi
Jason S. Bradfield
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 6/2016
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-016-0305-9

Other articles of this Issue 6/2016

Current Heart Failure Reports 6/2016 Go to the issue

Comorbidities of Heart Failure (C Angermann, Section Editor)

Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

New Challenges in the Treatment of Patients With Left Ventricular Support: LVAD Thrombosis

Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications

Comorbidities of Heart Failure (C Angermann, Section Editor)

Obstructive Ventilatory Disorder in Heart Failure—Caused by the Heart or the Lung?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.